Advertisement
Screener

Opus Genetics, Inc. (IRD) Material Contracts

Opus Genetics, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-05-12: Form 10-Q; Exhibit 10.6; Description Amendment No. 2 to Consulting Agreement, dated as of April 10, 2026, by and between the Company and Jay S. Pepose, M.D..
  • 2026-05-12: Form 10-Q; Exhibit 10.5; Description Waiver and Omnibus Amendment of Note Purchase Agreement and Stock Purchase and Conversion Agreement, dated as of April 13, 2026, by and among Opus Genetics, Inc., OpusTX, LLC, certain Purchasers party thereto, and OPCM SA LLC..
  • 2026-04-07: Form 8-K; Exhibit 10.1; Description Form of Change in Control Bonus Agreement..
  • 2026-04-07: Form 8-K; Exhibit 10.2; Description Stock Purchase and Conversion Agreement, by and among Opus Genetics, Inc. and the Purchasers..
FiledFormExhibitDescription
2026-05-1210-Q10.6Amendment No. 2 to Consulting Agreement, dated as of April 10, 2026, by and between the Company and Jay S. Pepose, M.D.
2026-05-1210-Q10.5Waiver and Omnibus Amendment of Note Purchase Agreement and Stock Purchase and Conversion Agreement, dated as of April 13, 2026, by and among Opus Genetics, Inc., OpusTX, LLC, certain Purchasers party thereto, and OPCM SA LLC.
2026-04-078-K10.1Form of Change in Control Bonus Agreement.
2026-04-078-K10.2Stock Purchase and Conversion Agreement, by and among Opus Genetics, Inc. and the Purchasers.
2026-04-078-K10.1Note Purchase Agreement, by and among Opus Genetics, Inc., the Purchaser Agent and the Purchasers.
2026-03-1210-K10.161Amendment No. 1 to the Consulting Agreement, dated November 21, 2024, by and between the Company and Jay Pepose, M.D.
2026-02-198-K10.2Form of Registration Rights Agreement, by and among Opus Genetics, Inc. and the Purchasers.
2026-02-198-K10.1Form of Securities Purchase Agreement, by and among Opus Genetics, Inc. and the Purchasers.

Similar stocks

Stock NameCountryMarket CapPE Ratio
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63